國立虎尾科技大學 |

Hepatitis C virus treatment = highly effective therapy with direct acting antivirals and associated viral resistance /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Hepatitis C virus treatment/ edited by Kazuaki Chayama.
Reminder of title:	highly effective therapy with direct acting antivirals and associated viral resistance /
other author:	Chayama, Kazuaki.
Published:	Singapore :Springer Singapore : : 2017.,
Description:	vii, 75 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Hepatitis C - Treatment. -
Online resource:	http://dx.doi.org/10.1007/978-981-10-2416-0
ISBN:	9789811024160

Hepatitis C virus treatment = highly effective therapy with direct acting antivirals and associated viral resistance /
Hepatitis C virus treatmenthighly effective therapy with direct acting antivirals and associated viral resistance /[electronic resource] :edited by Kazuaki Chayama. - Singapore :Springer Singapore :2017. - vii, 75 p. :ill., digital ;24 cm.

This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.

ISBN: 9789811024160

Standard No.: 10.1007/978-981-10-2416-0doiSubjects--Topical Terms:

889072
Hepatitis C
--Treatment.

LC Class. No.: RC848.H425

Dewey Class. No.: 616.3623

Hepatitis C virus treatment = highly effective therapy with direct acting antivirals and associated viral resistance /
LDR:02330nam a2200301 a 4500 001 957441
003 DE-He213
005 20161101043346.0
006 m d
007 cr nn 008maaau
008 201118s2017 si s 0 eng d
020 $a 9789811024160 $q (electronic bk.)
020 $a 9789811024153 $q (paper)
024 7 $a 10.1007/978-981-10-2416-0 $2 doi
035 $a 978-981-10-2416-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC848.H425
072 7 $a MJJ $2 bicssc
072 7 $a MED031000 $2 bisacsh
082 0 4 $a 616.3623 $2 23
090 $a RC848.H425 $b H529 2017
245 0 0 $a Hepatitis C virus treatment $h [electronic resource] : $b highly effective therapy with direct acting antivirals and associated viral resistance / $c edited by Kazuaki Chayama.
260 $a Singapore : $c 2017. $b Springer Singapore : $b Imprint: Springer,
300 $a vii, 75 p. : $b ill., digital ; $c 24 cm.
520 $a This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.
650 0 $a Hepatitis C $x Treatment. $3 889072
650 0 $a Hepatitis C virus. $3 676881
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Hepatology. $3 673859
650 2 4 $a Virology. $3 644995
650 2 4 $a Drug Resistance. $3 782695
700 1 $a Chayama, Kazuaki. $3 1249030
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-981-10-2416-0
950 $a Medicine (Springer-11650)